Navegando por Autor "Oliveira, Wógenes Nunes de"
Agora exibindo 1 - 6 de 6
- Resultados por página
- Opções de Ordenação
TCC Betabloqueadores como indutores de diabetes tipo 2: uma revisão integrativa.(Universidade Federal do Rio Grande do Norte, 2024-12-15) Lopes, Milena Brito; Araújo, Ivonete Batista de; http://lattes.cnpq.br/3872552451523411; Souza, Karla Simone Costa de; http://lattes.cnpq.br/2262063068881600; Oliveira, Wógenes Nunes deIntrodução - Os betabloqueadores atuam como antagonista dos receptores adrenérgicos e são reconhecidos por seus efeitos cardiovasculares. Entretanto, alguns estudos apontam que o uso prolongado aumenta o risco de desenvolvimento de diabetes tipo 2. Objetivo - Identificar casos de diabetes tipo 2 decorrente do uso contínuo de medicamentos betabloqueadores. Material e Métodos - trata-se de uma revisão integrativa realizada no período de maio a agosto de 2024 em três bases de dados: Google Scholar, PubMed e ScienceDirect, utilizando os Medical Subject (MESH): “Beta Blockers”, “Diabetes”, “Type 2 Diabetes”, “Insulin resistance”, “Adrenergic Beta Antagonists”, “Adverse Drug Event”, “Adverse Reactions”, “Glucose Metabolism Disorder”, associados aos booleanos “AND” e “OR”: “Beta blockers” AND “Diabetes” AND “Insulin resistance” AND “Hyperglycemia”, “Adverse Drug Event” OR “Adverse Reactions” AND “beta adrenergic antagonist”, “Type 2 Diabetes” AND “Glucose Metabolism Disorder” AND “Adrenergic beta-Antagonists”. Os artigos foram selecionados baseados no acrônimo PCC que engloba a População acometida, o Conceito e o Contexto e nos critérios de inclusão: pesquisas com pacientes em uso prolongado de betabloqueador, sem história familiar de diabetes e diagnóstico prévio dessa patologia, artigos de acesso livre, publicados entre 2019 e 2014 e que abordavam o desenvolvimento de diabetes do tipo 2 a partir do uso prolongado de betabloqueadores. Resultados - Foram encontrados 250 artigos no PubMed, 96 na Elsevier/ScienceDirect e 878 no Google Scholar todos de caráter qualitativo. Somente 7 artigos responderam ao acrônimo e aos critérios de inclusão. Considerações finais - Embora o uso de betabloqueadores tenha sido associado ao maior risco de desenvolvimento de diabetes do tipo 2, ainda se fazem necessários mais estudos que comprovem a incidência de diabetes do tipo 2 como efeito adverso dos betabloqueadores.TCC Covering the skincare routine using a multifunctional product: development of facial booster microemulsion using the box- behnken design(Universidade Federal do Rio Grande do Norte, 2024-06-21) Cruz, Yasmin Ferreira da; Egito, Eryvaldo Sócrates Tabosa do; Oliveira, Wógenes Nunes de; 0000-0002-1564-906X; http://lattes.cnpq.br/1190614005046544; http://lattes.cnpq.br/6907806915889763; 0000-0002-7726-1933; http://lattes.cnpq.br/7115213545673756; Alencar, Éverton do Nascimento; 0000-0002-6148-6804; http://lattes.cnpq.br/0168495853673885; Ostrosky, Elissa Arantes; http://lattes.cnpq.br/8787499230023565The international cosmetic market has been highlighted for the production and commercialization of multifunctional products, characterized by incorporation of different active ingredients. Then, the development of microemulsions (ME) stands out due to its ability to deliver different active ingredients to obtain properties as moisturizing, photoprotective and antioxidant. Based on this, the aim of this study was to produce and characterize a multifunctional facial booster (MFB) based on a linseed oil ME containing vitamin E, hyaluronic acid (HA), and phenylbenzimidazole sulfonic acid (PBSA) by the Box-Benhken experimental design (BBD). The concentrations of the active ingredients were defined, based on the BBD results of antioxidant activity, sun protector factor (SPF) and occlusivity. The MFB was characterized by its antioxidant activity, occlusivity, SPF and spreadability in vitro. In addition, MFB was physicochemically characterized by hydrodynamic droplet size distribution, polydispersity index (PdI) and pH. The BBD proposed a MFB composed by HA 5 %, vitamin E 5 % and PBSA 7.5 %, that showed an antioxidant activity, SPF, occlusivity and spreadability of 8.02 ± 1.20 %, 12.65 ± 1.33, 27.65 ± 1.67 % and 2923 ± 167 mm², respectively. These results represent an effective radical scavenging, photoprotection, water loss inhibition and adequate spreadability. Moreover, MFB showed a droplet size, PdI and pH of 34.74 ± 0.14 nm, 0.184 ± 0.02, 7.14 ± 0.02, respectively. The MFB showed physicochemical characteristics suitable for microemulsion systems and presented suitable stability for 90 days. Finally, the MFB was successfully produced and stands itself as a promising multifunctional cosmetic product.Tese Desenvolvimento e avaliação in vitro do potencial cicatrizante de microemulsão para veiculação tópica do óleo de linhaça(Universidade Federal do Rio Grande do Norte, 2022-11-25) Oliveira, Wógenes Nunes de; Egito, Eryvaldo Socrates Tabosa do; Machado, Lucas Amaral; http://lattes.cnpq.br/6907806915889763; https://orcid.org/0000-0002-1564-906X; http://lattes.cnpq.br/1190614005046544; Medeiros, Aldo da Cunha; Sena, Elenara Teixeira Lemos; Magalhães, Nereide Stela Santos; Araújo Júnior, Raimundo Fernandes de; http://lattes.cnpq.br/1903940945895093Baseado na notória atividade cicatrizante do óleo de linhaça, atribuída a sua composição química, juntamente com os problemas relacionados ao seu uso in natura; este trabalho teve como objetivo a produção e caracterização de sistema microemulsionado para veiculação tópica do óleo de linhaça. Para isso, a microemulsão (MeLO) foi produzida em sonicador e caracterizada quanto ao diâmetro hidrodinâmico de gotícula, índice de polidispersividade (PdI), pH e condutividade. Em seguida, foi adicionada a goma xantana e então foram avaliadas a espalhabilidade, viscosidade e comportamento reológico. A avaliação in vitro da atividade cicatrizante ocorreu por meio do ensaio de cristal violeta e de migração celular. Assim, após a produção, a MeLO apresentou diâmetro hidrodinâmico médio de gotícula de 25,2 ± 3,8 nm e PdI de 0,20 ± 0,02; pH de 5,29 ± 0,08 e condutividade de 296 ± 2.1 μS/cm, os quais se mantiveram estáveis ao longo de 30 dias a 25 ± 2 °C. Adicionalmente, foi verificado espalhabilidade máxima de 2129 ± 277,13 mm² e viscosidade de 157 ± 9,51 cP para MeLO, a qual demonstrou comportamento reológico pseudoplástico. Além disso, tanto o óleo de linhaça in natura quanto a microemulsão foram capazes de estimular a proliferação e migração de células 3T3. Sendo assim, pode-se afirmar que a microemulsão a base do óleo de linhaça contendo goma xantana apresentou características promissoras para a aplicação tópica do óleo de linhaça como agente cicatrizante.TCC Development of aminophylline loaded mucoadhesive PCL-chitosan nanocapsules via double emulsion method(Universidade Federal do Rio Grande do Norte, 2024-06-20) Couto, Hericles Afonso de Carvalho; Egito, Eryvaldo Sócrates Tabosa do; Oliveira, Wógenes Nunes de; http://lattes.cnpq.br/1190614005046544; http://lattes.cnpq.br/6907806915889763; http://lattes.cnpq.br/1329511657990020; Silva Júnior, Arnóbio António da; http://lattes.cnpq.br/2593509584288129; Nogueira, Fernando Henrique Andrade; http://lattes.cnpq.br/3818421971151621Aminophylline (Am) is a drug used for pulmonary diseases due its bronchodi-lation and anti-inflammatory properties. However, its efficacy and clinical use are compromised by its side effects, reducing the patient compliance. To over-come this issue, polymeric nanocapsules (Nc) have emerged to enhance the bi-opharmaceutical properties of drugs. This study aimed to develop and charac-terize aminophylline nanocapsules (AmNc), as well as chitosan-coated amino-phylline nanocapsules (AmNc-Chi) with potential mucoadhesive properties. Using the double emulsion method, both Nc and AmNc were produced. The aminophylline was quantified using a UV-Vis spectrophotometry. Physico-chemical stability of AmNc was assessed, and an assay to determine the ideal chitosan concentration for producing AmNc-Chi via adsorption method. AmNc exhibited a particle size of 231.4 ± 13.6 nm, PdI of 0.278 ± 0.062, and zeta poten-tial of -22.1 ± 1.4 mV, while AmNc-Chi showed a particle size of 289.8 ± 36 nm, PdI of 0.230 ± 0.06, and zeta potential of +29.5 ± 5.6 mV. Both formulations maintained stability over 30 days, with high encapsulation efficiency (>96%). These results indicates that the nanosystem was successfully produced and could be a potential alternative to use the aminophylline in pulmonary diseases.TCC Development of moringa oil nanoemulsion for treatment of chronic wounds(Universidade Federal do Rio Grande do Norte, 2025-06-25) Lima, Wallacy Silva de; Egito, Eryvaldo Sócrates Tabosa do; Oliveira, Wógenes Nunes de; https://orcid.org/0000-0002-1564-906X; http://lattes.cnpq.br/1190614005046544; https://orcid.org/0000-0002-2180-3991; http://lattes.cnpq.br/6907806915889763; https://orcid.org/0009-0003-0624-5682; http://lattes.cnpq.br/1073079461813835; Silva Júnior, Arnóbio Antônio da; https://orcid.org/0000-0002-2180-3991; http://lattes.cnpq.br/2593509584288129; Veríssimo, Lourena Mafra; https://orcid.org/0000-0002-7516-1787; http://lattes.cnpq.br/9173400981540256; https://orcid.org/0000-0002-9289-0455Background/Objectives: Moringa oleifera Lam is highlighted in literature for its bioactive 10 properties as anti-inflammatory, antioxidant, and wound-healing, which are mainly at- 11 tributed to the fixed oil extracted from its seeds. Nevertheless, the oil organoleptic char- 12 acteristics as odor, viscosity, texture, and susceptibility to oxidation limit the in natura oil 13 topical application. Therefore, the aim of this study was the development of nanoemul- 14 sions containing moringa oil (MO) as a nanotechnological approach to enable a suitable 15 topical use. Methods: The Quality by Design (QbD) approach by Design of Experiments 16 (DoE) tool was used to determine the required HLB value (rHLB) of MO and develop the 17 nanoemulsion. Subsequently nanoemulsion was characterized by hydrodynamic droplet 18 size, polydispersity index, and zeta potential, followed by a preliminary stability study 19 under different storage conditions (4 ± 2 °C, 25 ± 2 °C, 45 ± 2 °C). Results: The required 20 HLB identified through DoE was 12.27. The nanoemulsion obtained by the QbD strategy 21 was composed by 10% of MO, 12% surfactant mixture (Kolliphor® RH 40 and Span® 80), 22 and 78% water. This composition produced a nanoemulsion with an average droplet size 23 of 89.94 ± 5.34 d.nm, a polydispersity index (PdI) of 0.14 ± 0.02, and a zeta potential of - 24 9.55 ± 0.195 mV. The final formulation exhibited typical characteristics of nanoemulsified 25 systems and adequate physicochemical stability for 90 days, demonstrating a promising 26 topical product. Conclusions: These results indicate the successful development and pre- 27 liminary characterization and stability for a nanoemulsion containing MO, paving the 28 way for its further evaluation and use on wound healing.TCC Hydrogel lens for incorporation of Brimonidine Tartrate: a pre-formulation study(Universidade Federal do Rio Grande do Norte, 2025-01-10) Medeiros, Mariana Maressa Ferreira de; Girão, Ícaro Chaves; Sousa, Fabia Julliana Jorge de; Oliveira, Douglas Dourado; Oliveira, Wógenes Nunes de; Egito, Eryvaldo Sócrates Tabosa do; Egito, Eryvaldo Sócrates Tabosa do; Oliveira, Wógenes Nunes de; http://lattes.cnpq.br/1190614005046544; http://lattes.cnpq.br/6907806915889763; http://lattes.cnpq.br/5460829943851936; Alencar, Éverton do Nascimento; http://lattes.cnpq.br/0168495853673885; Silva, André Leandro; http://lattes.cnpq.br/0712488767870940Approximately 11.9 million people suffer from vision impairment or blindness due to glaucoma, a condition characterized by progressive optic nerve damage that primarily affects peripheral vision and can lead to blindness. The brimonidine tartrate (BRT) eye drops, a third-generation alpha-adrenergic agonist, are commonly used for glaucoma treatment, however present (i) side effects, (ii) low ocular availability (1-7%), (iii) nasolacrimal drainage and (iv) compliance issues that compromise its continuous use, leading to the therapeutic inefficacy. Then, new drug delivery systems, such as hydrogel contact lenses, may improve the patient compliance, and promote suitable ocular drug delivery. Based on this, the aim of this study was to produce and characterize brimonidine tartrate-loaded hydrogel lenses (BRTHL). The BRTHL was prepared by dissolving PVA at 90 ºC, followed by the addition of sodium hydroxide and sodium trimetaphosphate for crosslinking, followed by BRT incorporation during the manufacturing process. Posteriorly, the BRTHL was evaluated concerning the drug entrapment efficiency by UV-Vis spectrophotometry, in addition to light transmittance, thickness measurements, swelling behavior and Fourier transform infrared spectroscopy (FTIR). The BRTHL demonstrated an average drug entrapment efficiency of 72% ± 7.72%, which corresponds to 4.00 ± 0.35 µg/mg of hydrogel, a value similar to the commercial BRT eye drops. The BRTHL exhibited over 95% of transmittance, indicating adequate optical clarity. The thickness measurements were within optimal ranges for oxygen permeability and showed an average of 0.192 ± 0.010 mm. The swelling behavior of the hydrogels showed efficient water absorption, supporting potential drug release. The FTIR results indicated the success of the crosslink process. Then, the developed BRTHL exhibited suitable physical and chemical properties, effective drug loading, and satisfactory light transmittance. The obtained results demonstrate their potential for ocular use, paving the way to its further use as a novel drug delivery system for BRT